Feature | October 14, 2011| Dave Fornell

FDA Panel Gives Unanimous Nod to Cook Medical’s Zilver PTX Drug-Eluting Stent

October 14, 2011 – A U.S. Food and Drug Administration (FDA) review panel gave its unanimous recommendation for the market approval of the Zilver PTX stent. It is the first device of its kind on several fronts to go before FDA review. It is the first drug-eluting stent (DES) for peripheral leg vessels, the first self-expanding DES and the first DES that does not use a polymer to load and elute its drug.

All 11 members of the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee voted Oct. 13 in favor of  Cook Medical's device on the basis of its safety, efficacy and acceptable risk profile. The recommendation is the latest step in the regulatory review process that the company hopes will ultimately lead to FDA approval to sell the Zilver PTX stent in the United States.

“Cook Medical is very pleased that the FDA’s Circulatory System Devices Panel has recognized the merits of Zilver PTX, and we look forward to a final decision on approval to market this device in the U.S. from the FDA in the coming months,” said Rob Lyles, vice president and global leader of Cook Medical’s peripheral intervention unit. “Cook Medical is dedicated to continually innovating and delivering medical devices that improve the quality of patient care worldwide, and we wholeheartedly feel Zilver PTX provides a great example of that patient-focused business philosophy.”

The FDA is not bound by decisions made by its panels, but usually follows their recommendations. Final FDA review will likely take place by the end of the year, or the beginning of 2012.

Following CE mark approval in 2009, Cook Medical’s Zilver PTX DES is now available for sale in 48 countries around the world including the United Kingdom, Germany, France, Brazil, New Zealand and Taiwan.

The stent is seen by many experts as a major step forward in treatment options for patients with peripheral artery disease (PAD) in the superficial femoral artery (SFA). Occlusions in the SFA are difficult to treat and frequently re-occlude.

Zilver PTX is made of nitinol, a shape memory metal alloy that will spring back into its original shape under axial, torsional and bending flexibility. Self-expanding stents are used in the SFA because of the need to torque and compress with the vessel.

The addition of the anti-tissue proliferation drug paclitaxel on the Zilver stent has shown promising results in clinical trials in lowering the usually high restenosis rates of SFA lesions.

Polymers used to load drugs and control drug elution on DES have been implicated as the culprit in late-stent thrombosis sometimes seen in coronary stents. Vendors have been researching ways to eliminate polymers, allowing DES to become a bare metal stent following full drug elution into the vessel wall. The Zilver PTX would be the first DES in the United States not to use polymer, which is seen by many interventional experts as the way of the future.

For more information: www.cookmedical.com

Related Content

Abbott Absorb bioresorbable stent, dissolving BVS, first West Coast implant, Good Samaritan Hospital Los Angeles
News | Stents Bioresorbable| July 19, 2016
Good Samaritan Hospital, Los Angeles, is the first hospital on the West Coast to offer patients with coronary artery...
VentureMed Group, Flex Scoring Catheter, FDA approval, peripheral arterial disease, PAD, endovascular treatment
Technology | Catheters| July 13, 2016
July 13, 2016 — VentureMed Group Ltd., specializing in devices for the endovascular treatment of...
Abbott, Absorb bioresorbable stent, University Hospitals Case Medical Center, first Midwest implant
News | Stents Bioresorbable| July 11, 2016
University Hospitals Case Medical Center, Cleveland, is among the first in the country – and the first in Ohio — to...
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, dissolving stent

The Abbott Absorb is the first bioresorbable stent to be cleared for use in the United States. 

Technology | Stents Bioresorbable| July 05, 2016 | Dave Fornell
July 5, 2016 — The U.S.
News | Stents Bioresorbable| June 06, 2016
Amaranth Medical announced that it completed enrollment in May in the RENASCENT-II study of its novel Aptitude 120-...
Biotronik, ORIENT trial results, EuroPCR 2016, Orsiro DES, hybrid drug-eluting stent
News | Stents Drug Eluting| June 03, 2016
Biotronik announced results establishing non-inferiority of the Orsiro hybrid drug-eluting stent (DES) to the Resolute...
News | Drug-Eluting Balloons| June 03, 2016
June 3, 2016 — Cardionovum GmbH recently announced the completion of enrollment of the RAPID trial.
congenital heart, pulmonary artery stenting, JACC study
News | Congenital Heart| May 31, 2016
In a recent study, the use of a stent to repair pulmonary artery stenosis in children and adults with congenital heart...
Biotronik, Magmaris bioresorbable magnesium scaffold, BIOSOLVE-II Trial, 12-month results, EuroPCR 2016
News | Stents Bioresorbable| May 17, 2016
Biotronik presented 12-month data from the BIOSOLVE-II trial during a Hotline Session at EuroPCR 2016.
Overlay Init